Biodegradable CpG DNA hydrogels for sustained delivery of doxorubicin and immunostimulatory signals in tumor-bearing mice

Biomaterials

Volumn 32, Issue 2, 2011, Pages 488-494

  Nishikawa, Makiya ^a   Mizuno, Yumiko ^a   Mohri, Kohta ^a   Matsuoka, Nao ^a   Rattanakiat, Sakulrat ^a   Takahashi, Yuki ^a   Funabashi, Hisakage ^b   Luo, Dan ^b   Takakura, Yoshinobu ^a  

^a KYOTO UNIVERSITY   (Japan)

^b Department of Biological and Environmental Engineering   (United States)

Author keywords

Controlled drug release; DNA; Drug delivery; Hydrogel; Immunostimulation

Indexed keywords

BUILDING UNITS; CANCER CELLS; CANCER TREATMENT; CO-CULTURE SYSTEM; CONTROLLED DRUG RELEASE; CYTOTOXIC EFFECTS; DELIVERY SYSTEMS; DOXORUBICIN; FIREFLY LUCIFERASE; IMMUNE CELLS; IMMUNOSTIMULATION; MURINE MACROPHAGES; OLIGODEOXYNUCLEOTIDES; SELF-ASSEMBLED; SUSTAINED SYSTEMS; TUMOR GROWTH; TUMOR NECROSIS FACTORS;

CELL CULTURE; CLONE CELLS; CLONING; CONTROLLED DRUG DELIVERY; HYDROGELS; MACROPHAGES; TUMORS;

DNA;

CPG OLIGODEOXYNUCLEOTIDE; DOXORUBICIN; FIREFLY LUCIFERASE; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA;

ADENOCARCINOMA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL CLONE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; DENDRITIC CELL; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG RELEASE; HYDROGEL; IMMUNOCOMPETENT CELL; IMMUNOSTIMULATION; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR VOLUME;

ADENOCARCINOMA; ANIMALS; CELL LINE; CELL LINE, TUMOR; DINUCLEOSIDE PHOSPHATES; DNA; DOXORUBICIN; DRUG CARRIERS; HYDROGELS; IMMUNIZATION; LUCIFERASES, FIREFLY; MACROPHAGES; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED ICR; MICROSCOPY, ELECTRON, SCANNING; TUMOR NECROSIS FACTOR-ALPHA;

MURINAE; MUS;

EID: 78449239906     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2010.09.013     Document Type: Article

References (33)

1. Weiner G.J. The immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides. J Leukoc Biol 2000, 68:455-463.
2. Bremers A.J., Parmiani G. Immunology and immunotherapy of human cancer: present concepts and clinical developments. Crit Rev Oncol Hematol 2000, 34:1-25.
3. Berzofsky J.A., Ahlers J.D., Belyakov I.M. Strategies for designing and optimizing new generation vaccines. Nat Rev Immunol 2001, 1:209-219.
4. Klinman D.M. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol 2004, 4:249-258.
5. Krieg A.M. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002, 20:709-760.
6. Klinman D.M., Yi A.K., Beaucage S.L., Conover J., Krieg A.M. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon γ. Proc Natl Acad Sci USA 1996, 93:2879-2883.
7. Sparwasser T., Miethke T., Lipford G., Erdmann A., Häcker H., Heeg K., et al. Macrophages sense pathogens via DNA motifs: induction of tumor necrosis factor-α-mediated shock. Eur J Immunol 1997, 27:1671-1679.
8. Kumagai Y., Takeuchi O., Akira S. TLR9 as a key receptor for the recognition of DNA. Adv Drug Deliv Rev 2008, 60:795-804.
9. Kuramoto Y., Nishikawa M., Hyoudou K., Yamashita F., Hashida M. Inhibition of peritoneal dissemination of tumor cells by single dosing of phosphodiester CpG oligonucleotide/cationic liposome complex. J Control Release 2006, 115:226-233.
10. Krieg A.M. Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene 2008, 27:161-167.
11. Mizuno Y., Naoi T., Nishikawa M., Rattanakiat S., Hamaguchi N., Hashida M., et al. Simultaneous delivery of doxorubicin and immunostimulatory CpG motif to tumors using a plasmid DNA/doxorubicin complex in mice. J Control Release 2010, 141:252-259.
12. Li Y., Tseng Y.D., Kwon S.Y., D'Espaux L., Bunch J.S., McEuen P.L., et al. Controlled assembly of dendrimer-like DNA. Nat Mater 2004, 3:38-42.
13. Nishikawa M., Rattanakiat S., Takakura Y. DNA-based nano-sized systems for pharmaceutical and biomedical applications. Adv Drug Deliv Rev 2010, 62:626-632.
14. Nishikawa M., Matono M., Rattanakiat S., Matsuoka N., Takakura Y. Enhanced immunostimulatory activity of oligodeoxynucleotides by Y-shape formation. Immunology 2008, 124:247-255.
15. Rattanakiat S., Nishikawa M., Funabashi H., Luo D., Takakura Y. The assembly of a short linear natural cytosine-phosphate-guanine DNA into dendritic structures and its effect on immunostimulatory activity. Biomaterials 2009, 30:5701-5706.
16. Um S.H., Lee J.B., Park N., Kwon S.Y., Umbach C.C., Luo D. Enzyme-catalysed assembly of DNA hydrogel. Nat Mater 2006, 5:797-801.
17. Hoffman A.S. Hydrogels for biomedical applications. Adv Drug Deliv Rev 2002, 54:3-12.
18. Um S.H., Lee J.B., Kwon S.Y., Li Y., Luo D. Dendrimer-like DNA-based fluorescence nanobarcodes. Nat Protoc 2006, 1:995-1000.
19. Lenert P., Goeken A.J., Ashman R.F. Extended sequence preferences for oligodeoxyribonucleotide activity. Immunology 2006, 117:474-481.
20. Phillips D.R., Greif P.C., Boston R.C. Daunomycin-DNA dissociation kinetics. Mol Pharmacol 1988, 33:225-230.
21. Hyoudou K., Nishikawa M., Umeyama Y., Kobayashi Y., Yamashita F., Hashida M. Inhibition of metastatic tumor growth in mouse lung by repeated administration of polyethylene glycol-conjugated catalase: quantitative analysis with firefly luciferase-expressing melanoma cells. Clin Cancer Res 2004, 10:7685-7691.
22. Chun C., Lee S.M., Kim C.W., Hong K.Y., Kim S.Y., Yang H.K., et al. Doxorubicin-polyphosphazene conjugate hydrogels for locally controlled delivery of cancer therapeutics. Biomaterials 2009, 30:4752-4762.
23. Manegold C., Gravenor D., Woytowitz D., Mezger J., Hirsh V., Albert G., et al. Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26:3979-3986.
24. Krishnamachari Y., Salem A.K. Innovative strategies for co-delivering antigens and CpG oligonucleotides. Adv Drug Deliv Rev 2009, 61:205-217.
25. Akiba H., Satoh M., Iwatsuki K., Kaiserlian D., Nicolas J.F., Kaneko F. CpG immunostimulatory sequences enhance contact hypersensitivity responses in mice. J Invest Dermatol 2004, 123:488-493.
26. Heikenwalder M., Polymenidou M., Junt T., Sigurdson C., Wagner H., Akira S., et al. Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat Med 2004, 10:187-192.
27. Matsuoka N, Nishikawa M, Mohri K, Rattanakiat S, Takakura Y. Structural and immunostimulatory properties of Y-shaped DNA consisting of phosphodiester and phosphorothioate oligodeoxynucleotides. J Control Release, in press.
28. Krieg A.M. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 2006, 5:471-484.
29. Yu D., Kandimalla E.R., Bhagat L., Tang J.Y., Cong Y., Tang J., et al. 'Immunomers'-novel 3'-3'-linked CpG oligodeoxyribonucleotides as potent immunomodulatory agents. Nucleic Acids Res 2002, 30:4460-4469.
30. Ivanov S., Dragoi A.M., Wang X., Dallacosta C., Louten J., Musco G., et al. A novel role for HMGB1 in TLR9-mediated inflammatory responses to CpG-DNA. Blood 2008, 110:1970-1981.
31. Judson I.R. Anthrapyrazoles: true successors to the anthracyclines?. Anticancer Drugs 1991, 2:223-231.
32. Talmadge J.E., Donkor M., Scholar E. Inflammatory cell infiltration of tumors: Jekyll or Hyde. Cancer Metastasis Rev 2007, 26:373-400.
33. Storm G., Steerenberg P.A., Emmen F., van Borssum Waalkes M., Crommelin D.J. Release of doxorubicin from peritoneal macrophages exposed in vivo to doxorubicin-containing liposomes. Biochim Biophys Acta 1988, 965:136-145.